The striking impact of enzymatic and organometallic catalysis on the design of environmentally friendly processes for the discovery and production of pharmaceutical products is discussed. Four case studies namely ST1535, Idarubicin, Rubitecan and 7ACA are analysed in the context of a modern synthetic design based on the application of the 12 green chemistry principles. (C) 2008 Elsevier B.V. All rights reserved.
Cabri W (2009). Catalysis: The pharmaceutical perspective. CATALYSIS TODAY, 140(1-2), 2-10 [10.1016/j.cattod.2008.07.014].
Catalysis: The pharmaceutical perspective
Cabri W
2009
Abstract
The striking impact of enzymatic and organometallic catalysis on the design of environmentally friendly processes for the discovery and production of pharmaceutical products is discussed. Four case studies namely ST1535, Idarubicin, Rubitecan and 7ACA are analysed in the context of a modern synthetic design based on the application of the 12 green chemistry principles. (C) 2008 Elsevier B.V. All rights reserved.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
